Ritu Baral

“I guess I have the same question in terms of edema, which is, I guess, related but separate in the sense that I think KOLs see that less as a true safety issue but potentially a tolerability issue.”

“One is basically Paul's question, but applied to the sweat chloride and basically any insight on into the increased variability they're seeing. Obviously, it's a notoriously variable measure in individual patients per the KOLs, and is there any insight in how to control that potentially for the 4-5-1 data?”

“The change in retinal fixation, in your experience, was that also related to anecdotal improvement in these patients or potential improvements on any PROs that you officially or unofficially measured?”

“One is related to just the time lag to revenues for Alevitis.”

“Wes, I wanted to ask about the deployment strategy of the 40 reps that you mentioned across the vascular anomaly clinics. Do you guys currently have an estimate of how many identified vascular anomaly clinics there are either now or at the time of the commercial launch since you mentioned more opening up.”